CCHR Warns: Millions of Children Exposed to Risky Psychiatric Drugs
LOS ANGELES, Calif., June 2, 2025 (SEND2PRESS NEWSWIRE) — A federal assessment of children's health has identified the widespread prescribing of psychotropic drugs to U.S. youth as a 'public crisis' driven by industry profit motives, flawed science, and systemic conflicts of interest. The U.S. Department of Health and Human Services (HHS) found that stimulants, antidepressants, antipsychotics, and anti-anxiety drugs were leading the surge.[1] According to the Citizens Commission on Human Rights International (CCHR) , a mental health industry watchdog, this is fueling a psychotropic drug market that reaps $22.6 billion annually.
CCHR advised parents to become better informed about the risks of psychotropic drugs, including benzodiazepines or anti-anxiety drugs prescribed to children. CCHR offers a 16-page educational booklet, Psychiatric Drugs & Your Child's Future , and the documentary Dead Wrong , which features bereaved parents who lost children to psychiatric drug effects, especially antidepressants—black box-warned for suicide in 2004, more than 15 years after Food and Drug Administration (FDA) approval.
HHS reported that prescriptions for stimulants rose 250% between 2006 and 2016. By 2022, 11% of all children—and nearly 25% of boys—had a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), despite no medical test to confirm the behavioral symptoms. Long-term trials of ADHD drugs show no academic, behavioral, or social benefit beyond 14 months—and a loss of height averaging one inch. Teen use of antidepressants increased 1,400% between 1987 and 2014, and over 2 million prescriptions were written for adolescents in 2022 alone.[2]
Antipsychotic drug use among children grew 800% between 1995 and 2009, with 66% prescribed off-label—including for ADHD and 'aggression.' Antipsychotics in adolescent boys may cause up to 5x more gynecomastia (male breast growth); 4x more extrapyramidal effects (movement disorders); and 6–8x more weight gain than placebo. Meanwhile, serious side effects—including seizures, cardiac issues, male breast growth, and prolonged withdrawal syndromes—are widely documented.[3]
CCHR, which has tracked what it calls mass-prescribed drug child abuse since its founding in 1969, said the situation is even more dire than the HHS report reveals. Using data from IQVia's Total Patient Tracker Database for 2020, CCHR found: 1 million 0–17-year-olds were prescribed ADHD stimulants,
15 million were on antidepressants,
15 million were taking anti-anxiety drugs, including highly addictive benzodiazepines, and
829,372 were prescribed antipsychotics known to cause neurological damage.[4]
Combined, over 6.1 million children and teens were drugged—representing more than 8.2% of the U.S. youth population.[5]
Psychotropic polypharmacy is especially prevalent among youth covered by Medicaid. A 2024 study found a rise in multiple drug use in this group, increasing the risk of adverse medical outcomes. Researchers reviewed 126,972 Medicaid recipients who had received at least one psychotropic drug and had continuous coverage for 90+ days. The prevalence of polypharmacy rose from 4.2% in 2015 to 4.6% in 2020, with higher rates among those in foster care (10.8% to 11.3%), the Children's Health Program (2.2% to 2.8%), and low-income households (2.1% to 2.8%).[6]
The problem is exacerbated by drug misuse. In 2018, almost 16% of U.S. college students said they misused prescription stimulants.[7] A 2023 survey of college students who reported using prescription stimulants revealed that about 21.7% had taken a higher-than-prescribed dose in the past three months.[8] Many students mistakenly believe one ADHD stimulant to be no more harmful than coffee, assuming it is safe because it's prescribed by doctors.[9]
Youth drug overdoses on prescription drugs is also a serious risk. In 2019, 4,777 U.S. youth died from drug overdoses; 727 involved benzodiazepines and 902 involved psychostimulants. In 2020, 2,928 nonfatal benzodiazepine overdoses were reported among youth aged 15 to 24. Among these, 29% had a prescription in the previous month and 42% within six months. Intentional overdoses were more likely among those with recent prescriptions. Fifty-six percent of benzodiazepine overdoses were intentional compared with 40% of stimulant overdoses.[10]
The FDA issued a black box warning in 2020 for benzodiazepines, citing 'risks of abuse, misuse, and addiction, which can lead to overdose or death.'[11]
A 2022 study in Pediatrics found that a quarter of insured teens who overdosed on anxiety or ADHD drugs had received a recent prescription.[12]
HHS linked the rise in drug use to broadened diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), expanded in 2013 by panels with financial ties to the pharmaceutical industry. This contributed to a 40-fold increase in childhood diagnoses such as ADHD and bipolar disorder. Yet, no psychiatric-defined disorder meets the scientific definition of a disease. Former U.S. National Institute of Mental Health Director Thomas Insel stated: 'Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure.'[13]
CCHR, established in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, has achieved significant reforms in this area, including a 2004 federal law prohibiting schools from forcing students onto psychotropic drugs as a requisite for their education. Jan Eastgate, President of CCHR International, said: 'Profit-driven psychiatry is putting children at risk with no science to justify diagnoses or drugs.' CCHR stresses that the nation's child mental health system requires a complete overhaul—eliminating treatments that expose children to suicide, addiction, physical harm, and institutional profiteering.
To learn more, visit: https://www.cchrint.org/2025/05/30/federal-report-confirms-psychotropic-drugging-children-national-crisis/
Sources:
[1] 'Making Our Children Healthy Again,' Make America Healthy Again Commission (MAHA), 22 May 2025, p. 54
[2] MAHA Report, pp. 16-17
[3] MAHA Report, pp. 54-56
[4] https://www.cchrint.org/psychiatric-drugs/children-on-psychiatric-drugs/
[5] https://www.childstats.gov/AMERICASCHILDREN/tables/pop1.asp
[6] 'Psychotropic Polypharmacy Trends Rise Among Child, Adolescent Medicaid Beneficiaries,' Psychiatric Times, 21 May 2024
[7] https://news.osu.edu/misuse-of-stimulants-remains-a-top-concern-on-college-campuses/
[8] https://www.statista.com/statistics/1125729/us-college-student-prescription-stimulant-overuse/
[9] 'Are You Surprised By the 4 Most Abused Study Drugs?' Detox.com, 28 Feb. 2018
[10] https://www.clinicaladvisor.com/news/teens-overdosing-prescribed-anxiety-adhd-medications/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC9097826/
[11] https://www.cchrint.org/2023/08/30/mental-health-watchdog-highlights-global-benzodiazepine-risks/ ; 'FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Includes potential for abuse, addiction, and other serious risks,' FDA, 23 Sept. 2020
[12] https://doi.org/10.1542/peds.2021-055226
[13] 'The NIMH Withdraws Support for DSM-5,' Psychology Today, 4 May 2003
MULTIMEDIA:
Image link for media: https://www.Send2Press.com/300dpi/25-0602-s2p-cchrcrisis-300dpi.jpg
Image caption: 'Profit-driven psychiatry is putting children at risk with no science to justify diagnoses or drugs.' – Jan Eastgate, President of CCHR International.
NEWS SOURCE: Citizens Commission on Human Rights
Keywords: Religion and Churches, Citizens Commission on Human Rights, CCHR International, CCHR International, Jan Eastgate, psychotropic drug market, LOS ANGELES, Calif.
This press release was issued on behalf of the news source (Citizens Commission on Human Rights) who is solely responsibile for its accuracy, by Send2Press® Newswire . Information is believed accurate but not guaranteed. Story ID: S2P126647 APNF0325A
To view the original version, visit: https://www.send2press.com/wire/cchr-warns-millions-of-children-exposed-to-risky-psychiatric-drugs/
© 2025 Send2Press® Newswire, a press release distribution service, Calif., USA.
RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT.
Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Thune's first big test as Senate leader has arrived with Trump's tax bill
WASHINGTON (AP) — Only six months into the job, Senate Majority Leader John Thune faces a massive challenge as he tries to quickly push President Donald Trump's sprawling tax and spending cuts package to passage with the support of a divided GOP conference. While most Republican senators are inclined to vote for the bill, Thune can stand to lose only four votes in the face of united Democratic opposition — and many more Republicans than that are critical of the version sent over by the House. To get it done by July 4 — Trump's deadline — Thune has to figure out how to balance the various, and sometimes conflicting, demands emerging from his members. And he has to do it in a way that doesn't endanger Republican support in the House, which passed the legislation by only one vote last month after weeks of contentious negotiations. It's a complicated and risky undertaking, one that is likely to define the first year of Thune's tenure and make or break his evolving relationship with Trump. 'This is when John's leadership is going to be desperately needed,' said North Carolina Sen. Thom Tillis, one of the Republican holdouts who is pushing back on the bill's quick phaseout of certain energy tax credits. 'You can say no all you want, as long as you don't say no to the wrong 51 people.' So far, the well-liked South Dakota Republican is in a good place, both with colleagues and the White House. Thune has worked closely with Trump, despite a rockier relationship at the end of Trump's first term. While acknowledging that the Senate will likely change the bill to address concerns about changes to Medicaid and other programs, Thune has repeatedly said that 'failure is not an option.' 'Individual pieces of it people don't like,' Thune said Tuesday. 'But in the end, we have to succeed.' To get there, Thune has been meeting in his office with senators to hear them out, bringing in his colleagues individually and in small groups to discuss portions of the bill. Republican senators say the outreach is a stark change from his predecessor, Mitch McConnell, who was more feared than loved and kept a tight circle of advisers. McConnell stepped down from the leadership post in January after almost two decades amid a series of health episodes and growing criticism from senators on the right flank, who felt that he consolidated power and ignored their concerns. 'It's very much a change,' said North Dakota Sen. Kevin Cramer. Thune has 'already made a lot of people happier by the listening part,' he said. One happier senator is Florida Sen. Rick Scott, who sparred openly with McConnell and ran against Thune to replace him. Scott, who criticizes the bill as not doing enough to cut federal spending, has also met with the new leader. 'I'd be very surprised if anybody doesn't believe he's receptive to their ideas,' Scott said of Thune. And when people feel heard, Scott said, 'there's a greater chance they will go along with something.' Thune has also carefully navigated his relationship with the president, after sharply criticizing Trump in 2020 for trying to overturn his election defeat. Trump declined to endorse Thune's reelection bid two years later. Thune endorsed South Carolina Sen. Tim Scott over Trump in the presidential primary before eventually endorsing Trump. The two made amends in the final months of Trump's presidential campaign and have since forged a working relationship of mutual benefit. Thune has stayed in close touch with the White House, visiting Trump several times to discuss the bill, including on Wednesday. While the collaborative approach has won favor from Trump and colleagues who were agitating for a change, Thune has a long way to go in a short time. Passing the legislation will require hard choices, and not every demand can be met. Still, Thune's South Dakota colleague, Republican Sen. Mike Rounds, says he has already proved himself a 'winner' with Trump and the conference by quickly moving the president's Cabinet nominations through the Senate mostly without controversy. The Senate also recently blocked California air regulations that Republicans have long opposed after Thune delayed the vote for weeks to assuage procedural concerns from GOP moderates like Maine Sen. Susan Collins. 'Everybody wants to work with John,' Rounds said. 'He's not making anybody mad right now.' Rounds says Thune has also learned how to crack down when he needs to. Since taking power, Thune has shortened Senate vote times that were sometimes stretching for hours to just 15 minutes, in most cases. It was a hard lesson for some senators, but it won him respect from Republicans and, privately, even some Democrats. But as they were adjusting to the change, some senators unexpectedly missed votes because of Thune's new policy, Rounds said. 'Did he get yelled at a little bit? Yeah,' he said. 'But once they got cut off once or twice, pretty soon they realized, if you want to vote, make it on time.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Axios
an hour ago
- Axios
Biden hits back at Trump over autopen investigation
Former President Biden pushed back on Wednesday night on President Trump's announcement of an investigation into his use of an autopen to sign orders that raised questions about his mental fitness. What they're saying: "Let me be clear: I made the decisions during my presidency. I made the decisions about the pardons, executive orders, legislation, and proclamations," Biden said in a statement shared with outlets including Axios. "Any suggestion that I didn't is ridiculous and false." "This is nothing more than a distraction by Donald Trump and Congressional Republicans who are working to push disastrous legislation that would cut essential programs like Medicaid and raise costs on American families, all to pay for tax breaks for the ultra-wealthy and big corporations," he added in the emailed statement.
Yahoo
an hour ago
- Yahoo
Gender-affirming care funding at risk in new bill
NEW YORK (PIX11) — The future of gender affirming care for some transgender people is up in the air as lawmakers in Washington, D.C., consider President Trump's 'big, beautiful bill.' An amendment added to the bill would prohibit federal Medicaid funding from being used for gender-affirming care for not only minors, but also transgender adults. More Local News David Kilmnick, with the LGBT Network, tells PIX11 News the bill also proposes removing gender transition coverage for people who use health insurance under the Affordable Care Act. Micah Schneider, a trans person who works for the LGBT Network, says there is so much fearmongering and misunderstanding about gender affirming care. Schneider said, 'Gender affirming care is literally anything that makes you feel good in your skin. Hair implants for cis gender men; gender affirming care. Breast augmentation; gender affirming care.' Schneider tells PIX11 News, 'We're just every day normal folk trying to live our lives.' Dr. Jennifer Osipoff, a pediatric endocrinologist at Stony Brook Medicine, said gender affirming care includes everything from counseling to hormone therapy to puberty blockers. Osipoff said, 'I am hopeful that insurance will continue to pay for these therapies, that is one of the things that I do discuss now, that I never did before with my patients, because they want to know the worst case.' She adds: 'I don't fault families at all for trying to think of a solution, because they're literally trying to keep their child healthy, happy, and alive.' Gender affirming surgery is only performed on individuals 19 and above at Stony Brook Medicine. The FBI issued an official statement via 'X' on June 2nd stating, 'Help the FBI protect children. As the Attorney General has made clear, we will protect our children and hold accountable those who mutilate them under the guise of gender-affirming care. Report tips of any hospitals, clinics, or practitioners performing these surgical procedures on children at 1-800-CALL-FBI or click here. The CDC reports that it is rare that gender affirming surgery is ever performed on minors. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
